AN2 Therapeutics, Inc. (ANTX) Stock Analysis & Investment Frameworks
AN2 Therapeutics, Inc. (ANTX) stock analysis on Invetso. Review AN2 Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
AN2 Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
AN2 Therapeutics, Inc. Key Financial Metrics
- Market Cap: $150.94M
- Revenue: $N/A
- ROE: -53.52%
- ROIC: -51.01%
- Dividend Yield: N/A
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
AN2 Therapeutics, Inc. Investment Frameworks
Invetso analyzes AN2 Therapeutics, Inc. (ANTX) across the following frameworks:
- AN2 Therapeutics, Inc. 10Y Growth Potential
- AN2 Therapeutics, Inc. Scenario Analysis
- AN2 Therapeutics, Inc. Risks & Opportunities
- AN2 Therapeutics, Inc. Economic Moat
- AN2 Therapeutics, Inc. Business Model
- AN2 Therapeutics, Inc. Management
- AN2 Therapeutics, Inc. SWOT Analysis
- AN2 Therapeutics, Inc. Porter's 5 Forces
- AN2 Therapeutics, Inc. PESTLE Analysis
- AN2 Therapeutics, Inc. ESG Analysis